| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.083 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.6 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.6 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.076 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |